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Caffeine and Airway Resistance  
Gwyn N. Crump, MD 
ABSTRACT 
This study investigated the effect of caffeine on airway resistance.  The subjects 
were drawn from volunteers (18-90 years old) in good health, with no major 
cardiopulmonary conditions.  
We found no association between the consumption of a single cup of the 
caffeinated beverage coffee and a decrease in airway resistance within one hour in a 
normal population of subjects as measured neither by impulse oscillometry nor with 
conventional spirometry.  It appears that any possible bronchodilatory effect of the 
caffeine from a single cup of coffee in a normal population is below the limit of detection 
of spirometry and impulse oscillometry or is not sufficiently expressed in the one-hour 
time frame of the study. 
The study did validate currently accepted methods of using the Jaeger impulse 
oscillometry (IOS) measurement for use at the University of South Florida (USF).  The 
impulse oscillometry technique was found to be a useful adjunct to conventional 
pulmonary function testing.  Conventional pulmonary function testing provides a useful 
measure of a person’s ability to breathe yet is difficult to perform and only indirectly 
guides the physician to the diagnosis of the pathology behind the person’s breathing 
 vi  
difficulties.  The impulse oscillometry technique may help the physician to noninvasively 
determine the location of a pulmonary obstruction by measurement of the dynamics of 
sound wave travel through the airways of the lungs.
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Introduction 
Caffeine 
 Mankind has been drinking caffeinated beverages for almost 5000 years with the 
discovery of brewed tea attributed to the Second Emperor of China, Shen Nung, also 
known as the divine healer.  Tea and coffee contain about 20-60 mg and 125-185 mg of 
caffeine respectively per cup and have been prized throughout their history as both 
stimulants and palliatives for respiratory disorders1, 2.  The efficacy of caffeine in asthma 
has been evaluated in a recent evidence based medicine review of clinical trials which 
concludes “Caffeine appears to improve airways modestly in people with asthma for up 
to four hours”3. 
Yet, still much is not known both about the mechanisms of action of caffeine and 
the extent to which the general population, consciously or unconsciously uses caffeine to 
self-medicate respiratory ailments.  Caffeine and its more active metabolic products, 
theophylline and theobromine have long demonstrated bronchodilator effects through 
relaxation of bronchial smooth muscle4.   They are phosphodiesterase (PDE) inhibitors 
and decrease the rate at which the intracellular second messengers cAMP and cGMP are 
degraded.  Phosphodiesterase inhibitors also increase diaphragmatic contractility and 
respiratory drive probably through adenosine receptor antagonism5.  Recently, 
theophylline has been shown to exercise immunomodulatory and anti-inflammatory 
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properties even at sub-bronchodilator doses and plasma levels6.  This has been confirmed 
by measurement of exhaled nitric oxide levels after caffeine consumption7. 
The discovery of tissue specific PDE isoenzymes in the 1970’s has led to interest 
in the development of selective PDE inhibitors such as roflumilast and cilomilast8, 9. 
Selective PDE4 inhibitors are hoped to offer improved anti-inflammatory effects and 
improved safety over nonspecific PDE inhibitors such as theophylline.  The PDE4 
specific inhibitors cilomilast and roflumilast are now in clinical trials and appear 
promising10-12.  
Spirometry 
Spirometry has great utility for the diagnosis of respiratory disorders, monitoring 
of pulmonary disease progression, and assessment of treatment efficacy.  It is a 
composite measure of lung function that reveals much about overall air exchange 
capability yet is less illuminating of the various factors contributing to obstructive and 
restrictive lung deficits.  These factors may include body habitus, chest wall elasticity, 
lung compliance, airway resistance, cystic air trapping, respiratory muscle weakness and 
CNS impairment13, 14.  Thus for obstructive lung disorders it has been desirable to 
directly measure airway resistance and many techniques have been developed to 
accomplish this15.  Unfortunately these methods of airway resistance measurement such 
as plethysmography and the forced oscillation technique have previously been unsuitable 
for clinical application due to complexity and cost. 
Impulse Oscillometry 
Recently an application of the forced oscillation technique known as impulse 
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oscillometry (IOS) has become available in a compact package.  This Jaeger 
Masterscreen IOS package is non-invasive and FDA approved for IOS and conventional 
spirometry measurements.  A diagram of the typical equipment is shown in Figure 116.   
Figure 1.  Impulse Oscillometer 
 
Mouthpiece 
 
Impulse oscillometry uses the pressure-flow relationship of artificial impulse-
shaped test signals produced by an external generator.  These artificial signals are 
superimposed on the normal tidal breathing waveform of the subject while he is breathing 
ambient air.  Fast Fourier Transform (FFT) and quotient calculation is performed to 
derive frequency versus impedance, resistance and reactance curves.  This data can then 
be used to describe airflow characteristics of the subjects’ lungs both in degree of and 
location of impairment16.  Useful respiratory impedance parameters include R5, total 
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respiratory resistance; R20, proximal respiratory resistance; and X5, distal capacitive 
reactance (inversely related to the compliance of the lung). 
Asthma 
Asthma is the intermittent obstruction of lung airways in response to intrinsic or 
environmental provocation such as allergens, physiologic stress or infection.  Asthma is 
thought to be under diagnosed both in the general population and the elderly.  Many 
times there is a history of wheezing, especially after viral infections.  Often childhood 
asthma enters remission in the second decade of life only to return in adulthood.  Asthma 
may occur after decades of pulmonary insult from tobacco smoking, occasionally 
secondary to workplace exposures, and sometimes explosively with no prior history of 
asthma17, 18.  
Reports on the use of over-the-counter bronchodilator medications in asthmatics 
indicate not only are asthmatics under diagnosed, but medically diagnosed asthmatics  
who self-treat are less likely to receive and use anti-inflammatory therapy19.  Modern 
anti-inflammatory therapy can both relieve the symptoms of and delay the progression of 
asthma.   Further reports of other self and alternative medicine treatments for asthma 
include herbal products, coffee, black tea, reflexology, acupuncture, massage therapy, 
homeopathy, aromatherapy, and spinal manipulation20-23.  Treatments, such as Chinese 
herbs, may have concerning safety profiles and unpredictable interactions with 
conventional medications24.  Even if these alternative therapies are partially efficacious, 
it may only delay the diagnosis of asthma until an episode of respiratory failure places 
the patient in a hospital emergency department. 
 5  
 Asthma is not the only cause of obstructive pulmonary pathology. Other 
obstructive lung pathologies include chronic obstructive lung disease (chronic bronchitis 
or emphysema), bronchiectasis, cystic fibrosis, and bronchiolitis25.  Recently it has been 
recognized that vocal cord dysfunction may present with asthma-like symptoms26. 
Each of these illnesses tends to obstruct different areas of the respiratory tree. Asthma 
tends to exercise a predominant effect on the bronchi (larger airways) while chronic 
obstructive lung disease tends to affect both large and small airways.  In bronchiectasis, 
there is dilatation of the bronchi with obstruction of the smaller distal airways.  Cystic 
fibrosis tends to initially affect the smaller airways with later evolution to bronchiectasis. 
 In contrast, bronchiolitis tends to affect the bronchioles (smaller airways).  Vocal cord 
dysfunction affects the flow of air through the larynx (voicebox). 
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Methods 
 
 The study was designed to investigate the question:  “Is there a significant 
bronchodilator effect observed in a normal population with the consumption of a single 
cup of caffeinated coffee?”  The hypotheses to be tested was:  “A bronchodilator effect as 
measured as total respiratory resistance at 5 Hz by impulse oscillometry will be observed 
in a normal population with the consumption of a single cup of caffeinated coffee after 
one hour.”  
Study Subjects 
Subjects by interview had no history of diagnosis of major cardiopulmonary 
conditions.  The sample consisted of 20 subjects with an approximately equal distribution 
of gender in the group.  
Subjects had to be of a certain age group to be eligible for the study: ages 18 to 90 
years old (dates of birth 1914-1986). If the subjects were of this age group and decided to 
participate in this study, each reviewed the informed consent and discussed the study and 
possible participation with the study physician. If a subject was interested in 
participating, the informed consent was be signed before any study-related test or 
procedure was done. After signing the informed consent, screening tests were completed 
to determine if a subject met the requirements to be in the study. 
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Potential candidates were screened to determine whether they could be considered 
“normal”. Screening tests include completing standard questionnaires, undergoing a 
physician’s interview, submitting to a physical examination and completing spirometry 
measurements. The questionnaires are shown in Appendix A.  The study physician 
investigator reviewed the questionnaire responses; interviewed the subjects and 
completed spirometry. All spirometry was performed according to American Thoracic 
Society specifications and predicted values were taken from Hankinson, Crapo and co-
workers values27.  In order to qualify, participants must have recorded a negative 
questionnaire response suggestive of heart problems such as chest pain, irregular 
heartbeats or uncontrolled high blood pressure.  They also must not have been receiving 
any medical treatment for any pulmonary condition. 
Data Collected 
Data was collected about the airway resistance of subjects using the Jaeger impulse 
oscillometer and conventional pulmonary function tests.  These tests were performed 
before and 60 minutes after coffee consumption and subjects were interviewed as to 
current and previous state of health, smoking history and current respiratory symptoms. 
Patients were interviewed before and after the test, filled out the questionnaires in 
Appendix A and asked to report any respiratory or sensory changes. 
Pulmonary Measurement and Analysis 
This study was performed in the respiratory investigations lab of the Occupational 
and Environmental Medicine Department at the College of Public Health at the 
University of South Florida, Tampa, FL.  Over a two-week period, twenty subjects were 
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interviewed and tested during a single one to two hour visit.  With the exception of the 
informed consent form, all documentation was only identified by subject number.  They 
filled out a questionnaire screening for major medical conditions, underwent an interview 
and received a screening exam.  They then filled out a pre-test symptom questionnaire, 
performed conventional spirometry and underwent impulse oscillometry.   Spirometry 
and impulse oscillometry were perfomed in a seated position for safety.  The subject was 
fitted with a nose clip and instructed in the performance of the forced expiratory 
maneuver.  The use of the spirometry equipment is illustrated in Figure 2.  Three 
acceptable maneuvers were obtained and the best was retained for comparison. 
Figure 2.  Use of Spirometry Equipment 
 
  The restrictor screen door (Figure 3a) on the impulse oscillometer was closed 
(Figure 3b) and the subject instructed on the IOS procedures.  The device was zeroed and 
the subject was then instructed to begin breathing through the mouthpiece while 
supporting his cheeks with his hands (Figure 4).  After thirty seconds of breathing 
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normally through the mouthpiece and acclimating to the device, thirty seconds of 
measurements were taken. 
 
Figure 3.  IOS Restrictor Screen Door 
 
Figure 4.  IOS Subject Hand Position 
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The subjects then received one eight ounce cup of premium caffeinated coffee 
and filled out a medical history questionnaire.  The coffee was the brand name Starbucks 
Breakfast Blend and was prepared according to the instructions received with the 
package of coffee.   One tablespoon (15 milliliters of dried ground coffee) per six ounces 
(180 milliliters) of water was prepared using a drip type coffee maker. One hour later the 
subjects again filled out a symptom questionnaire, performed conventional spirometry 
and underwent impulse oscillometry.  These questionnaires are shown in Appendix A.  
 The investigator then interviewed the subject and performed a post-test 
auscultation of the subject’s chest to conclude the subject’s visit. Jaeger impulse 
oscillometry and conventional spirometry data were collected using the Jaeger 
LabManager software.  It was then was integrated with medical history data in a 
Microsoft Excel spreadsheet and analyzed using the JMP 5.1 statistical program.   
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Results 
Study Sample Characteristics 
 The study sample of twenty subjects was split approximately equally between 
male(11) and female(9) subjects.  The age of the sample ranged from 26 to 68 years with 
a median age of 40 years.  Seventeen of the subjects were Caucasian, two were US-
Asian, and one was US-African.  Sixteen of the twenty subjects reported no health 
problems.  Health problems that were reported included mitral valve prolapse, migraine 
headaches, lower back pain, glaucoma, urinary stones, history of fractures, hypertension, 
and frequent urinary tract infections.    
 Pre and post coffee consumption symptoms were monitored by use of the 
questionnaires in Appendix A.  Subjects were asked to describe symptoms of heavy or 
difficulty in breathing, phlegm production, runny or irritated nasal passages, throat 
irritation or burning, sensation of weight or tightness of the chest and feeling of chest 
burning.  Each symptom was rated a numeric scale of none(1), very little(2), moderate 
amount(3) and very much(4).  Descriptive statistics for the study sample are shown in 
Table 2 and Appendices E and F.  Additional sample characterstics are detailed in Table 
1 and Appendices B, C and D. 
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Table 1.  Study Sample Characteristics 
   
  
Gender 
 
Female (9)                 45% 
Male (11)                  55% 
Race / Ethnicity Caucasian (17)           85% 
US African (1)           5% 
US Asian (2)              10% 
Age Range   26-68 years 
Median  40 years 
Mean   41.15 years 
Standard Deviation 9.76 years 
Health Problems None (16) 80%, Mitral valve prolapse (1) 5%,  
Migraine headaches (1) 5%, Lower back pain (1) 5%,  
Glaucoma (1) 5%, Urinary stones (1) 5%,  
History of fractures (1) 5%, Hypertension (1) 5%,  
Frequent urinary tract infections (1) 5% 
Medications None (10) 50%, Multivitamin (3) 15%, Calcium (1) 5%, 
Vitamin C (1) 5%, Saw palmetto (1) 5%, Lo Ovral (1) 5%, 
Tryoptic (1) 5%, Naprosyn (1) 5%, Premarin (1) 5%,  
OTC sinus medication (1) 5%, Yasmin (1) 5%, 
Spector (1) 5%, Paxil (1) 5% 
Tobacco Smoker 
 
 
No (15)                        75% 
Yes (3)                         15% 
Past (2)                        10% 
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Table 2. Pre and Post Coffee Symptom Questionnaire Results  
  Median Mean Standard Deviation 
Pre Coffee 1.000 1.150 0.489 Breathing 
Difficulties Post Coffee 1.000 1.100 0.447 
Pre Coffee 1.000 1.350 0.671 Phlegm 
Production Post Coffee 1.000 1.450 0.605 
Pre Coffee 1.000 1.200 0.523 Nasal 
Problems Post Coffee 1.000 1.100 0.308 
Pre Coffee 1.000 1.200 0.523 Throat 
Irritation Post Coffee 1.000 1.200 0.523 
Pre Coffee 1.000 1.150 0.366 Chest 
Tightness Post Coffee 1.000 1.050 0.224 
Pre Coffee 1.000 1.000 0.000 Chest 
Burning Post Coffee 1.000 1.000 0.000 
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Impulse Oscillometry Measurements 
 A significant trend could not be detected in impulse oscillometry measurements.  
The sample measurements appeared to be normally distributed and were analyzed using a 
matched pairs t-test.  The results are summarized in Table 3   and detailed in Appendices 
 G, I and J.  Mean pre-coffee total respiratory resistance at 5 Hz (R5) was 4.125.  Mean 
post-coffee R5 was 4.107.  The t value was -0.15236 and the probability of obtaining this 
t value through chance alone when there is no difference is 0.4403.  Therefore the null 
hypothesis failed to be rejected at alpha= 0.05.  Wilcoxon Sign-Rank test results were 
similar. 
Table 3.  Impulse Oscillometry Measurements  
 Median Mean Standard Deviation 
Pre-coffee R5 4.000 4.125 1.095 
Post-coffee R5 3.865 4.107 1.247 
  
Spirometric Measurements 
 A significant trend could not be detected in conventional spirometry 
measurements of forced expiratory ventilation in one second (FEV1).  The sample 
measurements did not appear to be normally distributed and therefore were analyzed 
using a matched pairs Wilcoxon Sign-Rank test.  The results are summarized in Table 4   
and detailed in Appendices H, I and J.  Median pre-coffee FEV1 was 3.430.  Median 
post-coffee FEV1 was 3.545.  The Wilcoxon Sign-Rank test value was 7.000 and the 
probability of obtaining this value through chance alone when there is no difference is 
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0.387.  Therefore this secondary measure also failed reach significance at alpha= 0.05.  
Matched pairs t-test results were similar. 
  
Table 4.  Spirometric Measurements  
 Median Mean Standard Deviation 
Pre-coffee FEV1 3.430 3.425 0.842 
Post-coffee FEV1 3.545 3.454 0.832 
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Discussion 
 This study compared respiratory parameters in a sample of normal subjects before 
and one hour after consumption of one cup of the caffeinated beverage coffee.  Although 
the study failed to show a significant difference in R5 before and after consumption of 
this beverage it did provide useful experience in the use of the Jaeger Impulse 
Oscillometer.  Further, this study failed to confirm a bronchodilator effect in normal 
individuals from consumption of caffeine as measured by changes in FEV1.  This stands 
in contrast to previous studies on asthmatics in which an increase in FEV1 was measured. 
 One possibility for the minimal changes observed in the study was that the study 
sample was too healthy.  Previous studies that demonstrated a bronchodilator effect were 
performed on asthmatics.  This study excluded known asthmatics. 
 Another explanation was that the interval of one hour between consumption of the 
coffee and measurement of lung parameters was too short to allow time for a significant 
bronchodilator effect to develop.  Some studies in asthmatics demonstrated a larger effect 
in intervals of  two to four hours.  It is possible that there is a measurable effect in a 
normal population but it takes longer than one hour to develop. 
 It is also possible that the dose of caffeine delivered by this coffee was less than 
that delivered by other brands or types of coffee.  No attempt was made to quantify the 
caffeine content of this coffee.  Although Starbucks Breakfast Blend Coffee was 
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presumed to have between 125 and 185 mg of caffeine per cup the actual caffeine content 
of this blend is unknown to this researcher.  Caffeine has complex pharmacodynamics 
and remains in the body for more than one day.  Thus in a habitual coffee drinker the 
effect may be masked by the previous days consumption of coffee. 
 There may simply be too much intra-subject and inter-subject variability in the in 
the amount of bronchodilation and bronchoconstriction existing even in normal subjects 
in response to environmental stimuli and personal characteristics from day to day and 
hour to hour.  This “noise” would tend to mask small effects. 
 This study could be repeated on asthmatic subjects to characterize their response 
to caffeine using the IOS.  The caffeine dose given could be exactly determined and 
subjects could be asked to abstain from caffeine for more than just overnight.  Finally the 
study could be performed over a longer period of time on normal subjects to determine 
when a bronchodilatory effect occurs in normal subjects.   
 The study could be repeated with a greater attempt to control subjects activity and 
confounding exposures in the interval between the pre and post caffeine pulmonary 
measurements.  The subjects were allowed to leave the lab area in the interval  between 
being given the coffee and the post coffee respiratory measurements.  By requiring the 
test subjects to remain in the lab area during the entire duration of the study the activities 
of the subjects can be monitored and external exposures could be controlled.   
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Conclusions 
 There was no evidence of bronchodilation induced one hour after consumption of 
a single cup of caffeinated coffee in normal individuals neither as measured by impulse 
oscillometry nor by conventional spirometry. 
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Appendix A: Questionnaires 
Subject number:_______ 
Caffeine and Airway Resistance Study Pre-Coffee 
Questionnaire 
 
 
Today’s Date _______________________________________ 
 
People who are pregnant or have heart problems such as chest pain, irregular 
heartbeats or uncontrolled high blood pressure should not drink caffeinated beverages 
such as coffee.  
  
Do you have any health problems that would prevent you from drinking coffee or 
have you been told by a doctor, nurse or other healthcare provider that you should 
avoid caffeinated beverages such as coffee? 
                      
Please circle “yes” or “no”. 
   
  YES      or      NO         
 
Do you take any medications from a doctor or other healthcare provider for your 
lungs? 
 
Please circle “yes” or “no”. 
   
  YES      or      NO        
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Appendix A: (Continued) 
 
SUBJECT NUMBER: 
___________________________________________  
Pre-Coffee Consumption Symptom Questionnaire  
 
 
“At this point in time, to what degree do you note the following 
symptoms?”  
 
(1) Heavy or difficulty in your breathing 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(2) Phlegm production 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(3) Runny or irritated nose or nasal passages 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(4) Throat irritation or burning sensation 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(5) Sensation of a “weight” or tightness of the chest  
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(6) Feeling of chest burning 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
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Appendix A: (Continued) 
 
 
SUBJECT NUMBER: 
___________________________________________  
Post-Coffee Consumption Symptom Questionnaire  
 
“At this point in time, to what degree do you note the following 
symptoms?”  
 
(1) Heavy or difficulty in your breathing 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(2) Phlegm production 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(3) Runny or irritated nose or nasal passages 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(4) Throat irritation or burning sensation 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(5) Sensation of a “weight” or tightness of the chest  
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
 
(6) Feeling of chest burning 
1. ? NONE  2. ? VERY LITTLE  3. ? MODERATE AMOUNT  4. ? VERY MUCH  
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Appendix A: (Continued) 
Subject number:_______ 
Caffeine and Airway Resistance Study Questionnaire 
 
Today’s Date _______________________________________ 
 
Gender:                Male           Female        (circle one) 
 
1) How old are you? ______________years 
2)   Do you have any health problems that you see a physician for? Please list them 
below. 
                     1._________________________________________________________ 
                      
 
                     2. ________________________________________________________ 
 
                         
                     3. ________________________________________________________ 
 
 
                     4. ________________________________________________________ 
 
 
                      5.________________________________________________________ 
 
 
3) Are you taking any medications?  If so please list them below. (Including over the 
counter medications) 
 
                     1._________________________________________________________ 
                      
 
                     2. ________________________________________________________ 
 
                         
                     3. ________________________________________________________ 
 
 
                     4. ________________________________________________________ 
 
 
                      5.________________________________________________________ 
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Appendix A: (Continued) 
 
4) If you have ever smoked, answer the following. 
 
                     How many packs per day did you smoke? ________________________ 
 
 
                     For how many years did you smoke? ____________________________ 
 
 
                     When did you stop smoking? __________________________________ 
 
 
5) On what date were you last ill? _________________________________________ 
 
 
 
6) What illness did you have? ____________________________________________ 
 
 
 
7) What is your occupation? _____________________________________________ 
 
 
 
8) Are you exposed to second hand smoke at home or at work? Please circle “yes” or 
“no”. 
   
  YES      or      NO         
 
9) Were you or are you exposed to any gases, dusts, or fumes at your job? 
 
                   YES      or       NO 
 
           If so, please explain:    ____________________________________________ 
 
 
_____________________________________________________________________ 
 
 
10) Do you ever wheeze or become short of breath?  Please circle “yes” or “no”. 
   
  YES      or      NO         
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Appendix B: Study Sample Characteristics 
Gender Ethnicity Age Health Problems Medications Smoker Pack-years
Male Caucasian 36 None None Past 1
Female US-Asian 37 None MVI, calcium No 0
Female Caucasian 26 None MVI No 0
Female US-Asian 35 None None No 0
Male Caucasian 39 None None No 0
Female Caucasian 48 None MVI, vitamin C No 0
Male Caucasian 35 None None No 0
Male Caucasian 36 None Saw palmetto No 0
Female Caucasian 40 MVP, migraine, LBP Lo Ovral Yes 15
Male Caucasian 42 None None Yes 0.1
Female Caucasian 42 None None No 0
Male Caucasian 42 Glaucoma, stones, fx Tryoptic, naprosyn No 0
Female Caucasian 54 None Premarin, OTC sinus No 0
Male Caucasian 45 None None No 0
Female Caucasian 26 None Yasmin Past 0.5
Male Caucasian 68 None Spector No 0
Male Caucasian 32 None None No 0
Male Caucasian 52 Hypertension None No 0
Female Caucasian 48 Frequent UTIs Paxil Yes 8
Male US-African 40 None None No 0
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Appendix C: Age, Gender and Ethnicity Distributions 
Distributions 
Gender 
Female
Male
 
Frequencies 
Level  Count Prob
Female 9 0.45000
Male 11 0.55000
Total 20 1.00000
 
 N Missing 
     0 
     2 Levels 
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Appendix C: (Continued) 
Ethnicity 
Caucasian
US-African
US-Asian
 
 
 
Frequencies 
Level  Count Prob
Caucasian 17 0.85000
US-African 1 0.05000
US-Asian 2 0.10000
Total 20 1.00000
 
 N Missing 
     0 
     3 Levels 
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Appendix C: (Continued) 
Age 
20
30
40
50
60
70
 
 
 
Quantiles 
    
100.0% maximum 68.000
99.5%  68.000
97.5%  68.000
90.0%  53.800
75.0% quartile 47.250
50.0% median 40.000
25.0% quartile 35.250
10.0%  26.600
2.5%  26.000
0.5%  26.000
0.0% minimum 26.000
 
Moments 
  
Mean 41.15
Std Dev 9.7617675
Std Err Mean 2.1827976
upper 95% Mean 45.718648
lower 95% Mean 36.581352
N 20
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Appendix D: Health Characteristics and Exposures Distributions 
Health Problems 
Frequent UTIs
Glacoma, stones, fx
Hypertension
MVP, migraine, LBP
None
 
 
Frequencies 
Level  Count Prob
Frequent UTIs 1 0.05000
Glacoma, stones, fx 1 0.05000
Hypertension 1 0.05000
MVP, migraine, LBP 1 0.05000
None 16 0.80000
Total 20 1.00000
 
 N Missing 
     0 
     5 Levels 
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Appendix D: (Continued) 
Medications 
Lo Ovral
MVI
MVI, calcium
MVI, vitamin C
None
Paxil
Premarin, OTC sinus
Saw palmetto
Spector
Tryoptic, naprosyn
Yasmin
 
 
Frequencies 
Level  Count Prob
Lo Ovral 1 0.05000
MVI 1 0.05000
MVI, calcium 1 0.05000
MVI, vitamin C 1 0.05000
None 10 0.50000
Paxil 1 0.05000
Premarin, OTC sinus 1 0.05000
Saw palmetto 1 0.05000
Spector 1 0.05000
Tryoptic, naprosyn 1 0.05000
Yasmin 1 0.05000
Total 20 1.00000
 
 N Missing 
     0 
    11 Levels 
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Appendix D: (Continued) 
Smoker 
No
Past
Yes
 
 
Frequencies 
Level  Count Prob
No 15 0.75000
Past 2 0.10000
Yes 3 0.15000
Total 20 1.00000
 
 N Missing 
     0 
     3 Levels 
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Appendix D: (Continued) 
Pack-years 
0
5
10
15
 
 
 
Quantiles 
    
100.0% maximum 15.000
99.5%  15.000
97.5%  15.000
90.0%  7.300
75.0% quartile 0.075
50.0% median 0.000
25.0% quartile 0.000
10.0%  0.000
2.5%  0.000
0.5%  0.000
0.0% minimum 0.000
 
Moments 
  
Mean 1.23
Std Dev 3.6992318
Std Err Mean 0.8271734
upper 95% Mean 2.9612938
lower 95% Mean -0.501294
N 20
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Appendix D: (Continued) 
Months Since Sick 
0
5
10
15
20
25
 
 
 
Quantiles 
    
100.0% maximum 24.000
99.5%  24.000
97.5%  24.000
90.0%  22.000
75.0% quartile 12.000
50.0% median 2.000
25.0% quartile 1.000
10.0%  0.750
2.5%  0.500
0.5%  0.500
0.0% minimum 0.500
 
Moments 
  
Mean 6.25
Std Dev 7.7577505
Std Err Mean 2.073346
upper 95% Mean 10.729192
lower 95% Mean 1.7708082
N 14
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Appendix D: (Continued) 
Occupation 
Case Mgr.
City Planner
Coast Guard
Engineer
Military
Physician
Rad. Clerk
Reg. Nurse
Secretary
Student
 
 
Frequencies 
Level  Count Prob
Case Mgr. 1 0.05000
City Planner 1 0.05000
Coast Guard 1 0.05000
Engineer 1 0.05000
Military 1 0.05000
Physician 9 0.45000
Rad. Clerk 1 0.05000
Reg. Nurse 2 0.10000
Secretary 2 0.10000
Student 1 0.05000
Total 20 1.00000
 
 N Missing 
     0 
    10 Levels 
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Appendix D: (Continued) 
Exposures 
None
indirect tobacco
workplace
 
 
Frequencies 
Level  Count Prob
None 16 0.80000
indirect tobacco 2 0.10000
workplace 2 0.10000
Total 20 1.00000
 
 N Missing 
     0 
     3 Levels 
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Appendix D: (Continued) 
Wheeze/SOB 
No
Yes
 
 
 
Frequencies 
Level  Count Prob
No 19 0.95000
Yes 1 0.05000
Total 20 1.00000
 
 N Missing 
     0 
     2 Levels 
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Appendix E: Pre and Post Coffee Symptom Questionnaire Results 
Pre Breathing Post Breathing Pre Phlegm Post Phlegm Pre Nose Post Nose 
1 1 1 2 1 1
1 1 1 2 1 1
1 1 1 2 1 1
1 1 3 2 1 1
1 1 1 2 1 1
3 3 3 3 2 2
1 1 2 1 3 2
1 1 1 1 1 1
2 1 1 2 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 2 2 2 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 2 1 1 1
1 1 1 1 1 1
 
Pre Throat Post Throat Pre Tightness Post Tightness Pre Burning Post Burning 
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
3 3 2 2 1 1
2 2 2 1 1 1
1 1 1 1 1 1
1 1 2 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
2 2 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
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Appendix F: Pre and Post Coffee Symptom Questionnaire Distributions 
Distributions 
Pre Breathing 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  1.9000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.15
Std Dev 0.4893605
Std Err Mean 0.1094243
upper 95% Mean 1.3790278
lower 95% Mean 0.9209722
N 20
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Appendix F: (Continued) 
Post Breathing 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  1.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.1
Std Dev 0.4472136
Std Err Mean 0.1
upper 95% Mean 1.3093024
lower 95% Mean 0.8906976
N 20
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Appendix F: (Continued) 
Pre Phlegm 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  2.9000
75.0% quartile 1.7500
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.35
Std Dev 0.6708204
Std Err Mean 0.15
upper 95% Mean 1.6639536
lower 95% Mean 1.0360464
N 20
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Appendix F: (Continued) 
Post Phlegm 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  2.0000
75.0% quartile 2.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.45
Std Dev 0.6048053
Std Err Mean 0.1352386
upper 95% Mean 1.7330576
lower 95% Mean 1.1669424
N 20
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Appendix F: (Continued) 
Pre Nose 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  2.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.2
Std Dev 0.5231484
Std Err Mean 0.1169795
upper 95% Mean 1.444841
lower 95% Mean 0.955159
N 20
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Appendix F: (Continued) 
Post Nose 
0.75
1
1.25
1.5
1.75
2
2.25
 
 
 
Quantiles 
    
100.0% maximum 2.0000
99.5%  2.0000
97.5%  2.0000
90.0%  1.9000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.1
Std Dev 0.3077935
Std Err Mean 0.0688247
upper 95% Mean 1.2440518
lower 95% Mean 0.9559482
N 20
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Appendix F: (Continued) 
Pre Throat 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  2.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.2
Std Dev 0.5231484
Std Err Mean 0.1169795
upper 95% Mean 1.444841
lower 95% Mean 0.955159
N 20
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Appendix F: (Continued) 
Post Throat 
0.5
1
1.5
2
2.5
3
3.5
 
 
 
Quantiles 
    
100.0% maximum 3.0000
99.5%  3.0000
97.5%  3.0000
90.0%  2.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.2
Std Dev 0.5231484
Std Err Mean 0.1169795
upper 95% Mean 1.444841
lower 95% Mean 0.955159
N 20
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Appendix F: (Continued) 
Pre Tightness 
0.75
1
1.25
1.5
1.75
2
2.25
 
 
 
Quantiles 
    
100.0% maximum 2.0000
99.5%  2.0000
97.5%  2.0000
90.0%  2.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.15
Std Dev 0.3663475
Std Err Mean 0.0819178
upper 95% Mean 1.3214559
lower 95% Mean 0.9785441
N 20
 
 50  
Appendix F: (Continued) 
Post Tightness 
0.75
1
1.25
1.5
1.75
2
2.25
 
 
 
Quantiles 
    
100.0% maximum 2.0000
99.5%  2.0000
97.5%  2.0000
90.0%  1.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1.05
Std Dev 0.2236068
Std Err Mean 0.05
upper 95% Mean 1.1546512
lower 95% Mean 0.9453488
N 20
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Appendix F: (Continued) 
Pre Burning 
0.75
1
1.25
1.5
1.75
2
2.25
 
 
 
Quantiles 
    
100.0% maximum 1.0000
99.5%  1.0000
97.5%  1.0000
90.0%  1.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1
Std Dev 0
Std Err Mean 0
upper 95% Mean 1
lower 95% Mean 1
N 20
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Appendix F: (Continued) 
Post Burning 
0.75
1
1.25
1.5
1.75
2
2.25
 
 
 
Quantiles 
    
100.0% maximum 1.0000
99.5%  1.0000
97.5%  1.0000
90.0%  1.0000
75.0% quartile 1.0000
50.0% median 1.0000
25.0% quartile 1.0000
10.0%  1.0000
2.5%  1.0000
0.5%  1.0000
0.0% minimum 1.0000
 
Moments 
  
Mean 1
Std Dev 0
Std Err Mean 0
upper 95% Mean 1
lower 95% Mean 1
N 20
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Appendix G: Impulse Oscillometry Measurements 
 
Pre R5 Pre R5 %ile Post R5 Post R5 %ile R5 Change R5 %ile Chg 
3.85 138.3 3.57 128.2 -0.28 -10.1 
3.43 94.3 2.72 74.9 -0.71 -19.4 
5.04 146.2 4.78 138.7 -0.26 -7.5 
5.99 166.4 7.29 202.5 1.3 36.1 
4.44 157.5 4.01 142.1 -0.43 -15.4 
3.18 83.3 3.26 85.2 0.08 1.9 
4.25 153.4 4.49 161.9 0.24 8.5 
6.94 249.1 6.21 223 -0.73 -26.1 
3.29 89.2 3.07 83.4 -0.22 -5.8 
2.64 92.6 2.9 101.6 0.26 9 
4.05 109 3.55 95.4 -0.5 -13.6 
3.2 112.3 3.3 115.9 0.1 3.6 
4.17 106.3 4.37 111.3 0.2 5 
3.45 119.6 4.51 156.2 1.06 36.6 
5.25 152.4 5.28 153.3 0.03 0.9 
4.44 141.3 4.54 144.7 0.1 3.4 
2.64 96.4 2.44 89.1 -0.2 -7.3 
4.91 165.6 5.34 180.2 0.43 14.6 
3.95 103.5 3.72 97.4 -0.23 -6.1 
3.39 119.6 2.79 98.5 -0.6 -21.1 
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Appendix H: Spirometric Measurements 
Pre FEV1 Pre FEV1 %ile Post FEV1 Post FEV1 %ile FEV1 Change FEV1 %ile Chg
4.17 102 4.26 104.3 0.09 2.3
2.54 88.2 2.36 82 -0.18 -6.2
3.53 103.4 3.48 102.2 -0.05 -1.2
2.12 74.6 2.02 71.1 -0.1 -3.5
3.03 82.8 3.67 100.3 0.64 17.5
2.64 99.7 2.95 111.2 0.31 11.5
3.65 73.5 3.65 73.6 0 0.1
4.42 117.8 4.2 111.9 -0.22 -5.9
2.78 98.9 2.9 103.1 0.12 4.2
4.27 93.1 4.28 93.2 0.01 0.1
2.89 107.3 2.59 95.9 -0.3 -11.4
3.75 81.7 3.8 82.7 0.05 1
2.34 79.9 2.33 79.7 -0.01 -0.2
4.42 110.6 4.37 109.3 -0.05 -1.3
2.83 91.4 3.05 98.5 0.22 7.1
2.84 81.2 2.98 85.3 0.14 4.1
5.41 103.7 5.41 103.6 0 -0.1
3.67 92.6 3.61 91.2 -0.06 -1.4
3.33 115.3 3.35 116 0.02 0.7
3.87 80.3 3.83 79.5 -0.04 -0.8
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Appendix I: Respiratory Measurements Distributions 
Pre FEV1 
2
2.5
3
3.5
4
4.5
5
5.5
 
 
 
Quantiles 
    
100.0% maximum 5.4100
99.5%  5.4100
97.5%  5.4100
90.0%  4.4200
75.0% quartile 4.0950
50.0% median 3.4300
25.0% quartile 2.7925
10.0%  2.3600
2.5%  2.1200
0.5%  2.1200
0.0% minimum 2.1200
 
Moments 
  
Mean 3.425
Std Dev 0.8416119
Std Err Mean 0.1881901
upper 95% Mean 3.8188865
lower 95% Mean 3.0311135
N 20
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Appendix I: (Continued) 
Pre FEV1 %ile 
70
80
90
100
110
120
 
 
 
Quantiles 
    
100.0% maximum 117.80
99.5%  117.80
97.5%  117.80
90.0%  114.83
75.0% quartile 103.63
50.0% median 92.85
25.0% quartile 81.33
10.0%  75.13
2.5%  73.50
0.5%  73.50
0.0% minimum 73.50
 
Moments 
  
Mean 93.9
Std Dev 13.459843
Std Err Mean 3.0097123
upper 95% Mean 100.1994
lower 95% Mean 87.6006
N 20
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Appendix I: (Continued) 
Post FEV1 
2
2.5
3
3.5
4
4.5
5
5.5
 
 
 
Quantiles 
    
100.0% maximum 5.4100
99.5%  5.4100
97.5%  5.4100
90.0%  4.3610
75.0% quartile 4.1075
50.0% median 3.5450
25.0% quartile 2.9125
10.0%  2.3330
2.5%  2.0200
0.5%  2.0200
0.0% minimum 2.0200
 
Moments 
  
Mean 3.4545
Std Dev 0.8318431
Std Err Mean 0.1860058
upper 95% Mean 3.8438145
lower 95% Mean 3.0651855
N 20
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Appendix I: (Continued) 
Post FEV1 %ile 
70
80
90
100
110
120
 
 
 
Quantiles 
    
100.0% maximum 116.00
99.5%  116.00
97.5%  116.00
90.0%  111.83
75.0% quartile 104.13
50.0% median 97.20
25.0% quartile 82.17
10.0%  74.19
2.5%  71.10
0.5%  71.10
0.0% minimum 71.10
 
Moments 
  
Mean 94.73
Std Dev 13.468681
Std Err Mean 3.0116886
upper 95% Mean 101.03354
lower 95% Mean 88.426463
N 20
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Appendix I: (Continued) 
Pre R5 
2
3
4
5
6
7
 
 
 
Quantiles 
    
100.0% maximum 6.9400
99.5%  6.9400
97.5%  6.9400
90.0%  5.9160
75.0% quartile 4.7925
50.0% median 4.0000
25.0% quartile 3.3150
10.0%  2.6940
2.5%  2.6400
0.5%  2.6400
0.0% minimum 2.6400
 
Moments 
  
Mean 4.125
Std Dev 1.0950775
Std Err Mean 0.2448668
upper 95% Mean 4.637512
lower 95% Mean 3.612488
N 20
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Appendix I: (Continued) 
Pre R5 %ile 
100
150
200
250
 
 
 
Quantiles 
    
100.0% maximum 249.10
99.5%  249.10
97.5%  249.10
90.0%  166.32
75.0% quartile 153.15
50.0% median 119.60
25.0% quartile 98.18
10.0%  89.54
2.5%  83.30
0.5%  83.30
0.0% minimum 83.30
 
Moments 
  
Mean 129.815
Std Dev 39.016411
Std Err Mean 8.7243346
upper 95% Mean 148.07524
lower 95% Mean 111.55476
N 20
 
 61  
Appendix I: (Continued) 
Post R5 
2
3
4
5
6
7
8
 
 
 
Quantiles 
    
100.0% maximum 7.2900
99.5%  7.2900
97.5%  7.2900
90.0%  6.1230
75.0% quartile 4.7200
50.0% median 3.8650
25.0% quartile 3.1175
10.0%  2.7270
2.5%  2.4400
0.5%  2.4400
0.0% minimum 2.4400
 
Moments 
  
Mean 4.107
Std Dev 1.2474146
Std Err Mean 0.2789304
upper 95% Mean 4.690808
lower 95% Mean 3.523192
N 20
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Appendix I: (Continued) 
Post R5 %ile 
50
100
150
200
 
 
 
Quantiles 
    
100.0% maximum 223.00
99.5%  223.00
97.5%  223.00
90.0%  200.27
75.0% quartile 155.47
50.0% median 122.05
25.0% quartile 95.90
10.0%  83.58
2.5%  74.90
0.5%  74.90
0.0% minimum 74.90
 
Moments 
  
Mean 129.175
Std Dev 41.41872
Std Err Mean 9.2615074
upper 95% Mean 148.55956
lower 95% Mean 109.79044
N 20
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Appendix I: (Continued) 
Pre R20 
2.5
3
3.5
4
4.5
5
5.5
 
 
 
Quantiles 
    
100.0% maximum 5.3200
99.5%  5.3200
97.5%  5.3200
90.0%  4.8010
75.0% quartile 3.9500
50.0% median 3.4650
25.0% quartile 3.1825
10.0%  2.6470
2.5%  2.5500
0.5%  2.5500
0.0% minimum 2.5500
 
Moments 
  
Mean 3.595
Std Dev 0.7431901
Std Err Mean 0.1661824
upper 95% Mean 3.9428237
lower 95% Mean 3.2471763
N 20
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Appendix I: (Continued) 
Post R20 
2
2.5
3
3.5
4
4.5
5
5.5
6
 
 
 
Quantiles 
    
100.0% maximum 5.9200
99.5%  5.9200
97.5%  5.9200
90.0%  5.1760
75.0% quartile 4.2725
50.0% median 3.2900
25.0% quartile 2.8175
10.0%  2.4950
2.5%  2.3200
0.5%  2.3200
0.0% minimum 2.3200
 
Moments 
  
Mean 3.5795
Std Dev 0.9626579
Std Err Mean 0.2152569
upper 95% Mean 4.0300378
lower 95% Mean 3.1289622
N 20
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Appendix I: (Continued) 
Pre X5 
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
 
 
 
Quantiles 
    
100.0% maximum -0.530
99.5%  -0.530
97.5%  -0.530
90.0%  -0.635
75.0% quartile -0.818
50.0% median -1.050
25.0% quartile -1.432
10.0%  -2.115
2.5%  -3.020
0.5%  -3.020
0.0% minimum -3.020
 
Moments 
  
Mean -1.223
Std Dev 0.5911283
Std Err Mean 0.1321803
upper 95% Mean -0.946343
lower 95% Mean -1.499657
N 20
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Appendix I: (Continued) 
Post X5 
-3
-2.5
-2
-1.5
-1
-0.5
0
 
 
 
Quantiles 
    
100.0% maximum -0.380
99.5%  -0.380
97.5%  -0.380
90.0%  -0.598
75.0% quartile -0.785
50.0% median -1.010
25.0% quartile -1.408
10.0%  -1.594
2.5%  -2.580
0.5%  -2.580
0.0% minimum -2.580
 
Moments 
  
Mean -1.116
Std Dev 0.4880078
Std Err Mean 0.1091219
upper 95% Mean -0.887605
lower 95% Mean -1.344395
N 20
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Appendix I: (Continued) 
Pre AX 
0
5
10
15
20
 
 
 
Quantiles 
    
100.0% maximum 20.040
99.5%  20.040
97.5%  20.040
90.0%  10.975
75.0% quartile 5.977
50.0% median 2.680
25.0% quartile 1.648
10.0%  1.099
2.5%  0.960
0.5%  0.960
0.0% minimum 0.960
 
Moments 
  
Mean 4.578
Std Dev 4.7440984
Std Err Mean 1.0608126
upper 95% Mean 6.7983064
lower 95% Mean 2.3576936
N 20
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Appendix I: (Continued) 
Post AX 
0
2.5
5
7.5
10
12.5
15
 
 
 
Quantiles 
    
100.0% maximum 13.260
99.5%  13.260
97.5%  13.260
90.0%  10.840
75.0% quartile 5.918
50.0% median 2.650
25.0% quartile 1.680
10.0%  0.979
2.5%  0.920
0.5%  0.920
0.0% minimum 0.920
 
Moments 
  
Mean 4.1095
Std Dev 3.7563048
Std Err Mean 0.8399353
upper 95% Mean 5.8675048
lower 95% Mean 2.3514952
N 20
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Appendix I: (Continued) 
Pre Fres 
7.5
10
12.5
15
17.5
20
22.5
 
 
 
Quantiles 
    
100.0% maximum 21.100
99.5%  21.100
97.5%  21.100
90.0%  20.509
75.0% quartile 14.698
50.0% median 12.555
25.0% quartile 8.777
10.0%  8.383
2.5%  7.980
0.5%  7.980
0.0% minimum 7.980
 
Moments 
  
Mean 12.7465
Std Dev 4.3390616
Std Err Mean 0.9702437
upper 95% Mean 14.777243
lower 95% Mean 10.715757
N 20
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Appendix I: (Continued) 
Post Fres 
7.5
10
12.5
15
17.5
20
22.5
 
 
 
Quantiles 
    
100.0% maximum 21.200
99.5%  21.200
97.5%  21.200
90.0%  20.611
75.0% quartile 15.015
50.0% median 11.940
25.0% quartile 8.957
10.0%  8.281
2.5%  7.920
0.5%  7.920
0.0% minimum 7.920
 
Moments 
  
Mean 12.589
Std Dev 4.2574367
Std Err Mean 0.9519918
upper 95% Mean 14.581542
lower 95% Mean 10.596458
N 20
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Appendix J: Analysis of Post-test vs Pre-test Differences in R5, R20 and FEV1 
Matched Pairs 
Difference: Post R5-Pre R5 
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Mean: (Post R5+Pre R5)/2
 
      
Post R5 4.107     t-Ratio -0.15236
Pre R5 4.125  DF 19
Mean Difference -0.018  Prob > |t| 0.8805
Std Error 0.11814  Prob > t 0.5597
Upper95% 0.22927  Prob < t 0.4403
Lower95% -0.2653   
N 20   
Correlation 0.90632   
Wilcoxon Sign-Rank 
  Post R5-Pre R5
Test Statistic -18.000
Prob > |z| 0.516
Prob > z 0.742
Prob < z 0.258
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Appendix J: (Continued) 
Matched Pairs 
Difference: Post R20-Pre R20 
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Mean: (Post R20+Pre R20)/2
 
      
Post R20 3.5795     t-Ratio -0.13075
Pre R20 3.595  DF 19
Mean Difference -0.0155  Prob > |t| 0.8973
Std Error 0.11855  Prob > t 0.5513
Upper95% 0.23262  Prob < t 0.4487
Lower95% -0.2636   
N 20   
Correlation 0.83723   
Wilcoxon Sign-Rank 
  Post R20-Pre R20
Test Statistic -27.000
Prob > |z| 0.330
Prob > z 0.835
Prob < z 0.165
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Appendix J: (Continued) 
Matched Pairs 
Difference: Post FEV1-Pre FEV1 
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Mean: (Post FEV1+Pre FEV1)/2
 
      
Post FEV1 3.4545     t-Ratio 0.654114
Pre FEV1 3.425  DF 19
Mean Difference 0.0295  Prob > |t| 0.5209
Std Error 0.0451  Prob > t 0.2604
Upper95% 0.12389  Prob < t 0.7396
Lower95% -0.0649   
N 20   
Correlation 0.97102   
Wilcoxon Sign-Rank 
  Post FEV1-Pre FEV1
Test Statistic 7.000
Prob > |z| 0.775
Prob > z 0.387
Prob < z 0.613
 
 
 
 
